New CEO in Specific Pharma: I look forward to take the lead in a unique growth company

On May 1st, the 53-year-old Uffe Kåre Jensen joins Specific Pharma as the company’s new CEO.

“I look forward to take the lead in a growth company and make Specific Pharma the largest player on the European market for Unlicensed Medicine. Making the right medicines available to patients with unmet medical needs constitutes a significant niche in the pharmaceutical industry. It is indeed a very exciting position in a unique company, both from a professional, management and personal perspective,” states the new CEO, Uffe Kåre Jensen.

Uffe Kåre Jensen has more than 20 years of experience from the pharmaceutical industry. Prior to joining Specific Pharma, he held a position as Disease Area Lead within the Cancer business area in Roche, and he has previously worked for Pfizer, Nycomed, Wyeth, and Teva.

Uffe Kåre Jensen has a BA in international marketing from Copenhagen Business School and a mini-MBA from IME-International Management Education. Originally, he was trained as a nurse. Thus, it is a man with a lot of experience from the pharmaceutical world that is about to lead the company on its journey to become the market leader for Unlicensed Medicines in Europe.

In addition to the position as CEO in Specific Pharma, Uffe Kåre Jensen joins the management team in the parent company, Nomeco. Henrik Kaastrup, CEO in Nomeco, is excited about the recruitment of a strong leader with profound experience from the industry and a great deal of professionalism.

“We are excited to have Uffe on board. Specific Pharma is undergoing an exciting phase of development, with focus on taking the company to the next level. One of the most important tasks for our new CEO is to ensure that Specific Pharma matures as a sustainable pharma company that can fulfill our growth ambitions,” says Henrik Kaastrup.
Specific Pharma has been growing quickly in recent years. It was established as a subsidiary of Nomeco in 2010 with two employees located in Copenhagen.

Today, Specific Pharma is present in 11 countries. The company is the market leader in the Nordic region, holds strong positions in the Baltics and the Netherlands, and is present in even more countries such as Serbia, Croatia, and Iceland. The company employs 22 people and helps an estimated 35,000 patients every year with access to medicine that, for one reason or another, is not available in the market.

Unlicensed Medicine is critical when patients are unable to get the right medical treatment with the products available in the markets, for instance in cases where the product is not registered in the country. Specific Pharma also assists companies involved in clinical trials with access to comparative drugs.

The new CEO, Uffe Kåre Jensen, is now taking the lead on the growth journey and the company’s mission to make the right medicines promptly available to patients with specific medical needs.

For further information: Henrik Kaastrup, CEO Nomeco: hka@nomeco.dk / + 45 2944 8649

Contact

Do you want Specific Pharma to contact you?




Request form By using this form you agree with the storage and handling of your data by this website.

x

Request

Please fill in as much as possible and send the request. We will answer your inquiry as soon as possible.














Temperature controlledLoggerNo special requirementsOther?


By using this form you agree with the storage and handling of your data by this website.